Corcept Therapeutics (CORT) Income from Continuing Operations (2010 - 2026)
Corcept Therapeutics (CORT) posted Income from Continuing Operations of 42987000.0 for Q2 2026, up 235.54% sequentially from 31715000.0 in Q1 2026, and up 22.15% YoY from 35192000.0 in Q2 2025.
Corcept Therapeutics (CORT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Income from Continuing Operations for 17 years, with the latest figure at 42987000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 22.15% year-over-year to 42987000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 55228000.0 (down 58.7% YoY) and the FY2025 annual result came in at 99652000.0, down 29.43% from the prior year.
- Income from Continuing Operations rose to 42987000.0 in Q2 2026 per CORT's latest filing, from 31715000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 47213000.0 in Q3 2024 and troughed at 31715000.0 in Q1 2026.
- A 5-year average of 25536666.67 and a median of 27645000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations soared 89.07% in 2023, then sank 254.35% in 2026.
- Over 5 years, Income from Continuing Operations stood at 16603000.0 in 2022, then surged by 89.07% to 31392000.0 in 2023, then declined by 1.96% to 30776000.0 in 2024, then declined by 21.08% to 24288000.0 in 2025, then surged by 76.99% to 42987000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 42987000.0, 31715000.0, and 24288000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 42.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.99 Mn |
| Mar 31, 2026 | -31.72 Mn |
| Dec 31, 2025 | 24.29 Mn |
| Sep 30, 2025 | 19.67 Mn |
| Jun 30, 2025 | 35.19 Mn |
| Mar 31, 2025 | 20.55 Mn |
| Dec 31, 2024 | 30.78 Mn |
| Sep 30, 2024 | 47.21 Mn |
| Jun 30, 2024 | 35.49 Mn |
| Mar 31, 2024 | 27.76 Mn |
| Dec 31, 2023 | 31.39 Mn |
| Sep 30, 2023 | 31.38 Mn |
| Jun 30, 2023 | 27.53 Mn |
| Mar 31, 2023 | 15.83 Mn |
| Dec 31, 2022 | 16.60 Mn |
| Sep 30, 2022 | 34.61 Mn |
| Jun 30, 2022 | 27.36 Mn |
| Mar 31, 2022 | 22.75 Mn |
| Dec 31, 2021 | 32.05 Mn |
| Sep 30, 2021 | 30.47 Mn |